About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01286987

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Study identifier: NCT01286987
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

BMN 673 (BioMarin)

Eligibility:

  • Breast cancer patients with deleterious or pathogenic BRCA mutations who have received no more than 4 prior regimens for metastatic disease.

Type of study:

Phase I

Treatment:

  • Patients receive BMN 673 orally once daily.

Study sites:

Arizona
TGen Clinical Research Services
Scottsdale, Arizona, 95258
Contact: Joyce Schaffer, MSN RN OCN 480-323-1339 joschaffer@shc.org
Principal Investigator: Ramesh Ramanathan, MD

California
University of California Los Angeles (UCLA)
Santa Monica, California, United States, 90404
Contact: Lisa M Yonemoto 310-582-4069 lyonemoto@mednet.ucla.edu
Principal Investigator: Zev Wainberg, MD

Indiana
Indiana University Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Principal Investigator: Lida Mina, MD
Contact: Ashley Grist 317-278-6680 acgrist@iupui.edu

Michigan
University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Nabeela Iqbal 734-232-0759 nabeela@umich.edu
Principal Investigator: Rashmi Chugh, MD

Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Lauren A Byers, MD
Contact: Beena Varghese-Cortes, RN 713-792-3850 babraham1@mdanderson.org
Contact: Griselda Parra gparra1@mdanderson.org

United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Contact: Sonia Serrano +44 (0) 20 8722 4087 Sonia.Serrano@icr.ac.uk
Principal Investigator: Johann de Bono, MD

Page updated 04/06/14


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org